Cyclin Kinase-independent role of p21CDKN1A in the promotion of nascent DNA elongation in unstressed cells

  1. Sabrina F Mansilla
  2. Agustina P Bertolin
  3. Valérie Bergoglio
  4. Marie-Jeanne Pillaire
  5. Marina A González Besteiro
  6. Carlos Luzzani
  7. Santiago G Miriuka
  8. Christophe Cazaux
  9. Jean-Sébastien Hoffmann
  10. Vanesa Gottifredi  Is a corresponding author
  1. Fundación Instituto Leloir-Instituto de Investigaciones Bioquímicas de Buenos Aires, Argentina
  2. Équipes Labellisées - La Ligue contre le Cancer, France
  3. Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia, Argentina

Abstract

The levels of the cyclin-dependent kinase (CDK) inhibitor p21 are low in S phase and insufficient to inhibit CDKs. We show here that endogenous p21, instead of being residual, it is functional and necessary to preserve the genomic stability of unstressed cells. p21depletion slows down nascent DNA elongation, triggers permanent replication defects and promotes the instability of hard-to-replicate genomic regions, namely common fragile sites (CFS). The p21's PCNA interacting region (PIR), and not its CDK binding domain, is needed to prevent the replication defects and the genomic instability caused by p21 depletion. The alternative polymerase kappa is accountable for such defects as they were not observed after simultaneous depletion of both p21 and polymerase kappa. Hence, in CDK-independent manner, endogenous p21 prevents a type of genomic instability which is not triggered by endogenous DNA lesions but by a dysregulation in the DNA polymerase choice during genomic DNA synthesis.

Article and author information

Author details

  1. Sabrina F Mansilla

    Fundación Instituto Leloir-Instituto de Investigaciones Bioquímicas de Buenos Aires, Buenos Aires, Argentina
    Competing interests
    The authors declare that no competing interests exist.
  2. Agustina P Bertolin

    Fundación Instituto Leloir-Instituto de Investigaciones Bioquímicas de Buenos Aires, Buenos Aires, Argentina
    Competing interests
    The authors declare that no competing interests exist.
  3. Valérie Bergoglio

    Équipes Labellisées - La Ligue contre le Cancer, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  4. Marie-Jeanne Pillaire

    Équipes Labellisées - La Ligue contre le Cancer, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  5. Marina A González Besteiro

    Fundación Instituto Leloir-Instituto de Investigaciones Bioquímicas de Buenos Aires, Buenos Aires, Argentina
    Competing interests
    The authors declare that no competing interests exist.
  6. Carlos Luzzani

    Laboratorio de Investigaciones Aplicadas en Neurociencias, Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia, Belén de Escobar, Argentina
    Competing interests
    The authors declare that no competing interests exist.
  7. Santiago G Miriuka

    Laboratorio de Investigaciones Aplicadas en Neurociencias, Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia, Belén de Escobar, Argentina
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-2402-3920
  8. Christophe Cazaux

    Équipes Labellisées - La Ligue contre le Cancer, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  9. Jean-Sébastien Hoffmann

    Équipes Labellisées - La Ligue contre le Cancer, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  10. Vanesa Gottifredi

    Fundación Instituto Leloir-Instituto de Investigaciones Bioquímicas de Buenos Aires, Buenos Aires, Argentina
    For correspondence
    vgottifredi@leloir.org.ar
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-9656-5951

Funding

National Institutes of Health (R03 TW008924)

  • Vanesa Gottifredi

Agencia Nacional de Promoción Científica y Tecnológica (PICT-2012-1371)

  • Vanesa Gottifredi

Agencia Nacional de Promoción Científica y Tecnológica (PICT-2013-1049)

  • Vanesa Gottifredi

Company of Biologists (Travel Fellowship)

  • Sabrina F Mansilla

Laboratoire d'Excellence Toulouse Cancer LABEX TOUCAN

  • Jean-Sébastien Hoffmann

La Ligue Nationale contra le Cancer

  • Jean-Sébastien Hoffmann

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2016, Mansilla et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,101
    views
  • 512
    downloads
  • 30
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Sabrina F Mansilla
  2. Agustina P Bertolin
  3. Valérie Bergoglio
  4. Marie-Jeanne Pillaire
  5. Marina A González Besteiro
  6. Carlos Luzzani
  7. Santiago G Miriuka
  8. Christophe Cazaux
  9. Jean-Sébastien Hoffmann
  10. Vanesa Gottifredi
(2016)
Cyclin Kinase-independent role of p21CDKN1A in the promotion of nascent DNA elongation in unstressed cells
eLife 5:e18020.
https://doi.org/10.7554/eLife.18020

Share this article

https://doi.org/10.7554/eLife.18020

Further reading

    1. Cancer Biology
    Han V Han, Richard Efem ... Richard Z Lin
    Research Article

    Most human pancreatic ductal adenocarcinoma (PDAC) are not infiltrated with cytotoxic T cells and are highly resistant to immunotherapy. Over 90% of PDAC have oncogenic KRAS mutations, and phosphoinositide 3-kinases (PI3Ks) are direct effectors of KRAS. Our previous study demonstrated that ablation of Pik3ca in KPC (KrasG12D; Trp53R172H; Pdx1-Cre) pancreatic cancer cells induced host T cells to infiltrate and completely eliminate the tumors in a syngeneic orthotopic implantation mouse model. Now, we show that implantation of Pik3ca−/− KPC (named αKO) cancer cells induces clonal enrichment of cytotoxic T cells infiltrating the pancreatic tumors. To identify potential molecules that can regulate the activity of these anti-tumor T cells, we conducted an in vivo genome-wide gene-deletion screen using αKO cells implanted in the mouse pancreas. The result shows that deletion of propionyl-CoA carboxylase subunit B gene (Pccb) in αKO cells (named p-αKO) leads to immune evasion, tumor progression, and death of host mice. Surprisingly, p-αKO tumors are still infiltrated with clonally enriched CD8+ T cells but they are inactive against tumor cells. However, blockade of PD-L1/PD1 interaction reactivated these clonally enriched T cells infiltrating p-αKO tumors, leading to slower tumor progression and improve survival of host mice. These results indicate that Pccb can modulate the activity of cytotoxic T cells infiltrating some pancreatic cancers and this understanding may lead to improvement in immunotherapy for this difficult-to-treat cancer.

    1. Cancer Biology
    2. Immunology and Inflammation
    Almudena Mendez-Perez, Andres M Acosta-Moreno ... Esteban Veiga
    Short Report

    In this study, we present a proof-of-concept classical vaccination experiment that validates the in silico identification of tumor neoantigens (TNAs) using a machine learning-based platform called NAP-CNB. Unlike other TNA predictors, NAP-CNB leverages RNA-seq data to consider the relative expression of neoantigens in tumors. Our experiments show the efficacy of NAP-CNB. Predicted TNAs elicited potent antitumor responses in mice following classical vaccination protocols. Notably, optimal antitumor activity was observed when targeting the antigen with higher expression in the tumor, which was not the most immunogenic. Additionally, the vaccination combining different neoantigens resulted in vastly improved responses compared to each one individually, showing the worth of multiantigen-based approaches. These findings validate NAP-CNB as an innovative TNA identification platform and make a substantial contribution to advancing the next generation of personalized immunotherapies.